EUVIMEDEUVIMED entdecken
Open Access

Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia

Mona S Abdellateif, Naglaa M Hassan, Mahmoud M Kamel, Yomna M El-Meligui

Oncology Research · 2024 · 32 (3) · 577-584

DOI: 10.32604/or.2023.043026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Mona S Abdellateif und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Medical Biochemistry and Molecular Biology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy, disease-free survival (DFS), and overall survival (OS) rates. Results: miR-34a was significantly downregulated in AML patients [0.005 (3.3 × 10-6-1.32)], compared to the control subjects [0.108 (3.2 × 10-4-1.64), p = 0.021]. The median relative quantification (RQ) of miR-34a was 0.106 (range; 0-32.12). The specificity, sensitivity, and area under the curve (AUC) for the diagnosis of AML were (58.3%, 69.5%, 0.707, respectively, p = 0.021). patients with upregulated miR-34a showed decreased platelets count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLeukemia, Myeloid, AcuteHumansBone MarrowPrognosisDisease-Free Survival

Stichwörter der Autor:innen

AMLLeukemiamiR-34amicroRNA

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Department of Cancer Biology, Medical Biochemistry and Molecular Biology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
  • Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.

Zitieren

APA

Abdellateif, M. S., Hassan, N. M., Kamel, M. M., & El-Meligui, Y. M. (2024). Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. Oncology Research, 32(3), 577-584. https://doi.org/10.32604/or.2023.043026

Vancouver

Abdellateif MS, Hassan NM, Kamel MM, El-Meligui YM. Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia. Oncology Research. 2024;32(3):577-584. doi:10.32604/or.2023.043026

BibTeX
@article{Abdellateif2024,
  author = {Abdellateif, Mona S and Hassan, Naglaa M and Kamel, Mahmoud M and El-Meligui, Yomna M},
  title = {Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia},
  journal = {Oncology Research},
  year = {2024},
  volume = {32},
  number = {3},
  pages = {577--584},
  doi = {10.32604/or.2023.043026}
}
Kostenlos starten →